SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Portfolio Pulse from
Sarepta Therapeutics' stock dropped over 20% following the death of a patient treated with its gene therapy, Elevidys, for Duchenne muscular dystrophy.
March 19, 2025 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics' stock fell significantly after a patient died following treatment with its gene therapy, Elevidys, for Duchenne muscular dystrophy.
The death of a patient following treatment with Sarepta's Elevidys gene therapy has raised safety concerns, leading to a significant drop in the company's stock price. This event is critical for investors as it directly impacts the perception and potential future sales of the therapy.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100